A Single Arm Open Label Study to Determine the Safety and Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Recurrence of Glioma in Patients Who Received a Prior Treatment With 186RNL

This is an open-label, multicenter, Phase 1 study to establish the safety and efficacy/tolerability of a single dose of 186RNL by the intraventricular route (via intraventricular catheter) for recurrence glioma in patients who received a prior treatment of 186RNL.

Start Date12 Dec 2024

Sponsor / Collaborator

Plus Therapeutics, Inc.

NCT05034497

/ Active, not recruitingPhase 1

A Multicenter Phase 1 Clinical Study to Determine the Maximum Tolerated Dose/Maximum Feasible Dose, Safety,& Efficacy of Single Dose Rhenium-186 NanoLiposome (186RNL) Administered Via Intraventricular Catheter for Leptomeningeal Metastases

This is an open-label Phase I clinical study that will administer a single dose of 186RNL via intraventricular catheter for treatment of Leptomeningeal Metastases (LM).

Start Date06 Dec 2021

Sponsor / Collaborator

Plus Therapeutics, Inc.

NCT01906385

/ RecruitingPhase 1/2

A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC# 12-02)

This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment. The study uses a modified Fibonacci dose escalation, followed by an expansion at the maximum tolerated dose (MTD) to determine efficacy. The starting absorbed dose is 1mCi in a volume of 0.660mL.

Start Date03 Jun 2015

Sponsor / Collaborator

Plus Therapeutics, Inc.

[+1]

100 Clinical Results associated with Retreatment Rhenium Liposome

100 Translational Medicine associated with Retreatment Rhenium Liposome

100 Patents (Medical) associated with Retreatment Rhenium Liposome

Literatures (Medical) associated with Retreatment Rhenium Liposome

04 Sep 2012·Molecular pharmaceuticsQ2 · MEDICINE

Feasibility of Eradication of Breast Cancer Cells Remaining in Postlumpectomy Cavity and Draining Lymph Nodes following Intracavitary Injection of Radioactive Immunoliposomes

Q2 · MEDICINE

Article

Author: Phillips, William T. ; Li, Shihong ; Bao, Ande ; Goins, Beth ; Hrycushko, Brian A.

Most diagnosed early stage breast cancer cases are treated by lumpectomy and adjuvant radiation therapy, which significantly decreases the locoregional recurrence but causes inevitable toxicity to normal tissue. By using a technique of preparing liposomes carrying technetium-99m ((99m)Tc), rhenium-186 ((186)Re), or rhenium-188 ((188)Re) radionuclides, as well as chemotherapeutic agents, or their combination, for cancer therapy with real time image-monitoring of pharmacokinetics and prediction of therapy effect, this study investigated the potential of a novel targeted focal radiotherapy with low systemic toxicity using radioactive immunoliposomes to treat both the surgical cavity and draining lymph nodes in a rat breast cancer xenograft positive surgical margin model. Immunoliposomes modified with either panitumumab (anti-EGFR) or bevacizumab (anti-VEGF) were remote loaded with (99m)Tc diagnostic radionuclide, and injected into the surgical cavity of female nude rats with positive margins postlumpectomy. Locoregional retention and systemic distribution of (99m)Tc-immunoliposomes were investigated by nuclear imaging, stereofluorescent microscopic imaging, and gamma counting. Histopathological examination of excised draining lymph nodes was performed. The locoregional retention of (99m)Tc-immunoliposomes in each animal was influenced by the physiological characteristics of the surgical site of individual animals. Panitumumab- and bevacizumab-liposome groups had higher intracavitary retention compared with the control liposome groups. Draining lymph node uptake was influenced by both the intracavitary radioactivity retention level and metastasis status. The panitumumab-liposome group had higher accumulation on the residual tumor surface and in the metastatic lymph nodes. Radioactive liposomes that were cleared from the cavity were metabolized quickly and accumulated at low levels in vital organs. Therapeutic radionuclide-carrying specifically targeted panitumumab- and bevacizumab-liposomes have increased potential compared to non-antibody targeted liposomes for postlumpectomy focal therapy to eradicate remaining breast cancer cells inside the cavity and draining lymph nodes with low systemic toxicity.

01 Jan 2008·Journal of drug targetingQ3 · MEDICINE

Imaging of¹⁸⁶Re-liposome therapy in ovarian cancer xenograft model of peritoneal carcinomatosis

Q3 · MEDICINE

Article

Author: Bao, Ande ; McMahan, C. Alex ; Goins, Beth A. ; McManus, Linda M. ; Phillips, William T. ; Zavaleta, Cristina L.

This study determined the biodistribution of rhenium-186 ((186)Re) encapsulated in biotin-liposomes containing patent blue dye, injected intraperitoneally (IP) with avidin in an OVCAR-3 ovarian cancer xenograft model and evaluated tumor response of this therapy with fluorine-18-fluorodeoxyglucose ((18)F-FDG) microPET imaging. Treated rats (n = 8) received an IP injection of (186)Re-blue-biotin-liposomes (1000 MBq/kg) 30 min before an IP injection of avidin (5 mg), whereas control rats (n = 4) received a sham IP injection of saline. Scintigraphic images showed that (186)Re-blue-biotin liposomes/avidin were retained in the peritoneal cavity with 18% of the original activity remaining after 5 days. From 1 to 4 weeks post-treatment, peritoneal (18)F-FDG standard uptake values decreased 30% in treatment group, yet increased 44% in control group. Total number of cells in ascites was significantly higher in control versus treatment group. Omental fat in control rats had numerous tumor cells compared with treated rats. Results show the potential for (186)Re-blue-biotin-liposome/avidin system in treating advanced ovarian cancer involving peritoneal carcinomatosis.

JOURNAL OF NUCLEAR MEDICINE

¹⁸⁶Re-liposome labeling using ¹⁸⁶Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats

Author: Phillips, William T. ; Goins, Beth ; Negrete, George ; Bao, Ande ; Klipper, Robert

Liposomes are important carriers for controlling the spatial and temporal distribution of drug mols. or other bioactive mols.Radiolabeled liposomes have potential applications in diagnostic imaging and radionuclide therapy.The purpose of this study was to develop a practical method for labeling liposomes with therapeutic rhenium radionuclides, using ¹⁸⁶Re as an example.Methods: An SNS pattern ligand, N,N-bis(2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA), and an S pattern ligand, benzene thiol (BT), were used to make 2 kinds of ¹⁸⁶Re-SNS/S complexes, ¹⁸⁶Re-BMEDA and ¹⁸⁶Re-BMEDA + BT.These ¹⁸⁶Re-SNS/S complexes were mixed with neutral liposomes encapsulating cysteine or (NH₄)₂SO₄ to prepare ¹⁸⁶Re-liposomes.The in vitro labeling stability of ¹⁸⁶Re-liposomes was investigated by incubation in 50% fetal bovine serum/50% phosphate-buffered saline, pH 7.4, at 37°C.Rat distribution studies of ¹⁸⁶Re-liposomes after i.v. injection were also performed.Results: The labeling efficiencies of ¹⁸⁶Re-liposomes were 52.9%-81.3% depending on the ¹⁸⁶Re-SNS/S complex chosen and whether cysteine- or (NH₄)₂SO₄-encapsulated liposomes were used.¹⁸⁶Re-(NH₄)₂SO₄ liposomes labeled with ¹⁸⁶Re-BMEDA had the best in vitro labeling stability in serum with 89.8% ± 3.1% of the radioactivity associated with liposomes at 24 h and 76.2% ± 5.1% at 96 h.A specific activity of 1.85 GBq (50 mCi) of ¹⁸⁶Re per 50 mg of phospholipid could be achieved with good labeling stability.Biodistributions were followed for 72 h and showed good in vivo stability for ¹⁸⁶Re-liposomes that was characterized by a slow blood clearance and a gradually increasing spleen accumulation.¹⁸⁶Re-BMEDA alone had fast blood clearance and no accumulation in spleen.Conclusion: A practical method for labeling liposomes with ¹⁸⁶Re using ¹⁸⁶Re-SNS/S complexes is described.The labeled ¹⁸⁶Re-liposomes were stable in serum and in vivo and could potentially be useful for radionuclide therapy.

News (Medical) associated with Retreatment Rhenium Liposome

23 Apr 2025

·www.globenewswire.com

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the appointment of Kyle Guse, J.D., M.B.A. to the Company’s Board of Directors where he will serve as chair of the Audit Committee and on the Compensation Committee. “Kyle’s decades of financial, transactional and operational experience in our industry will make an immediate and positive impact to Plus’ board of directors,” said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. “Furthermore, in his role as audit chair, Kyle will be a force in the successful execution of Plus’ ambitious business plan and driving stockholder value.” Mr. Guse is an executive with 30 years of professional experience leading the world’s most innovative companies. For over a decade he served as Chief Financial Officer, General Counsel and Secretary of Atossa Therapeutics, Inc., a NASDAQ-listed company developing a drug to prevent and treat breast cancer, which had previously developed and marketed medical devices, and that owned and operated a CLIA certified laboratory. Currently, he serves as Chief Legal Officer of DDC Enterprise Ltd., an NYSE-listed international consumer foods company. Formerly, he was a partner and practiced corporate law at several of the top international law firms. Prior to that, he was a Certified Public Accountant with a Big 4 accounting firm. He earned his J.D. (cum laude) from Santa Clara University Law School and an M.B.A. from California State University, Sacramento, where he also earned his Bachelor of Science degree. “Plus Therapeutics has multiple and significant opportunities in both the therapeutics and diagnostics markets with REYOBIQ™ (rhenium Re186 obisbemeda) and CNSide, and I believe it has tremendous potential to make an impact on the market,” said Mr. Guse. “I’m looking forward to collaborating closely with the Board and with management to help bring the Company to its full potential for stockholders, practitioners, and patients.” About Plus TherapeuticsHeadquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://plustherapeutics.com/. Cautionary Statement Regarding Forward-Looking StatementsThis press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential promise of REYOBIQ™, expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates; the Company’s clinical trials, including statements regarding the timing and characteristics of the ReSPECT-LM single dose and multi-dose clinical trials; the continued evaluation of rhenium (186Re) obisbemeda including through evaluations in additional patient cohorts. The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company’s product candidates and therapies; the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash; the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it; market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field; ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms; challenges associated with radiotherapeutic manufacturing, production and distribution capabilities necessary to support the Company’s clinical trials and any commercial level product demand; and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics’ business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics’ annual report on Form 10-K for the fiscal year ended December 31, 2024, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so. Investor ContactCORE IRinvestor@plustherapeutics.com

Executive Change

21 Apr 2025

·www.globenewswire.com

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

April 15, 2025 -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the online availability of new data on its lead compound REYOBIQ™ (rhenium Re186 obisbemeda) in an abstract for both an oral presentation and a poster to be presented at the Nuclear Medicine and Neurooncology conference to be held May 9-10, 2025 in Vienna, Austria. The abstract, titled, “Rhenium Obisbemeda (REYOBIQ) in Leptomeningeal Metastases,” highlights additional data from the Company’s completed Phase 1 ReSPECT-LM dose escalation trial demonstrating a dose dependent increase in the average absorbed dose to the cranial and spinal subarachnoid space reaching 253Gy in Cohort 5. Neuroimaging response data was available for 16 patients as of the data cutoff with five of those (31%) showing a partial response. An additional seven patients showed stable disease by neuroimaging through day 112 for a Clinical Benefit Rate (complete response + partial response + stable disease) of 75%. Additionally, a clinical response based on the physician evaluation showed a decrease in disease findings in two of 14 evaluable patients (14%) and 10 patients showed stable findings through day 112 for an 86% Clinical Benefit Rate. Furthermore, there was no dose limiting toxicity (DLT) observed in the first four cohorts, with a grade 4 DLT (thrombocytopenia), one in each of Cohorts 5 and 6. Finally, RNA sequencing of LM cells showed early induction of apoptosis, with an innate immune response followed by an increase in T cells and an adaptive immune response by Day 28. Further details can be found here; the Company will provide additional data and explanation following the meeting. "This newly-presented ReSPECT-LM data further reinforces our confidence in the potential utility of REYOBIQ in these critically ill patients with the devastating diagnosis of Leptomeningeal Metastases," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Reyobiq can be delivered at very high doses of radiation to the cancer at the recommended phase 2 dose and shows promising response data across multiple parameters while simultaneously being well tolerated by normal organs and tissues." LM is a rare complication of cancer in which the primary cancer spreads to the cerebrospinal fluid (CSF) and leptomeninges surrounding the brain and spinal cord. All malignancies originating from solid tumors, primary brain tumors, or hematological malignancies have this LM complication potential with breast cancer as the most common cancer linked to LM, with 3-5% of breast cancer patients developing LM. Additionally, lung cancer, GI cancers and melanoma can also spread to the CSF and result in LM. LM occurs in approximately 5% of people with cancer and is usually terminal with 1-year and 2-year survival of just 7% and 3%, respectively. The incidence of LM is on the rise, partly because cancer patients are living longer and partly because many standard chemotherapies cannot reach sufficient concentrations in the spinal fluid to kill the tumor cells, yet there are no FDA-approved therapies specifically for LM patients, who often succumb to this complication within weeks to several months, if untreated. REYOBIQ™ (rhenium Re186 obisbemeda) is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors in a safe, effective, and convenient manner to optimize patient outcomes. REYOBIQ™ has the potential to reduce off target risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging. REYOBIQ™ is being evaluated for the treatment of recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year $17.6M grant by the Cancer Prevention & Research Institute of Texas (CPRIT). Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://plustherapeutics.com/. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultRadiation TherapyASCO

07 Mar 2025

·www.pharmaceutical-technology.com

FDA ODD given to Plus Therapeutics’ injectable radiotherapy

The therapy is intended for LM in individuals with lung cancer. Credit: Jo Panuwat D/Shutterstock. The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Plus Therapeutics’ injectable radiotherapy, Rhenium ( 186 Re) Obisbemeda, for treating leptomeningeal metastases (LM) in lung cancer sufferers. The designation is awarded to drugs aimed at rare conditions (affecting fewer than 200,000 individuals in the US) and comes with benefits such as seven years of market exclusivity. The ODD for the therapy follows the completion of the single-dose Phase I ReSPECT-LM trial, which determined the recommended Phase II dose. Plus Therapeutics chief development officer Mike Rosol stated: “Receiving ODD for Rhenium ( 186 Re) Obisbemeda marks a significant milestone in our efforts to develop a much-needed therapy for lung cancer patients with leptomeningeal metastases. “This designation, in combination with our previously granted fast track designation, strengthens our pathway toward delivering an innovative, targeted radiotherapeutic solution for this highly underserved patient population.” Plus Therapeutics is currently progressing a Phase II single-dose expansion trial and a Phase I multiple-dose trial. The company is in discussions with the US regulator to establish the optimal pivotal trial strategy. A rare cancer complication, LM involves the spread of primary cancer to the cerebrospinal fluid and the leptomeninges around the spinal cord and brain. Designed to deliver targeted high-dose radiation to central nervous system (CNS) tumours, the therapy improves patient outcomes by offering a more potent radiation dose compared to existing therapies. The therapy is currently under assessment for recurrent glioblastoma and LM in the ReSPECT-GBM and ReSPECT-LM trials. Plus Therapeutics widened its collaboration with Piramal Pharma Solutions (PPS) in May 2023 to produce additional current good manufacturing practice liposome intermediate drug products .

Fast TrackOrphan DrugPhase 2Radiation TherapyClinical Result

100 Deals associated with Retreatment Rhenium Liposome

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Meningeal Neoplasms	Phase 2	-	Plus Therapeutics, Inc.	10 Oct 2023
Recurrent Glioma	Phase 2	United States	Plus Therapeutics, Inc.	03 Jun 2015
Recurrent Glioblastoma	Phase 2	-	Plus Therapeutics, Inc.	-
Metastatic Malignant Neoplasm to the Leptomeninges	Phase 1	United States	Plus Therapeutics, Inc.	06 Dec 2021
Central Nervous System Neoplasms	Clinical	United States	Piramal Pharma Solutions, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05034497 (ReSPECT-LM, GlobeNewswire) Manual	Phase 1	Metastatic Malignant Neoplasm to the Leptomeninges	20	Rhenium (186Re) Obisbemeda	fptwvpuyph(zzbhcxdcmr) = 1 dose-limiting toxicity (thrombocytopenia) observed in Cohort 5. lsihwbdfep (yismvmdics )	Positive	25 Nov 2024
ReSPECT-GBM (Corporate Publications) Manual	Phase 1/2	Glioblastoma	-	(186Re) Obisbemeda (phase 1(Cohorts 1-6))	futwhkofkt(kdxxrdtbtz) = Cohort 8 had 1 DLT hxgqorwbdy (newrsikwdt ) View more	Positive	30 Sep 2024
ReSPECT-GBM (Corporate Publications) Manual	Phase 1/2	Glioblastoma	-	(186Re) Obisbemeda (<100 Gy)		Positive	30 Sep 2024
NCT05034497 (ReSPECT-LM, GlobeNewswire) Manual	Phase 1	Metastatic Malignant Neoplasm to the Leptomeninges	16	Rhenium (186Re) Obisbemeda	sdulgztsrx(dizyrgvage) = urnlvnwirv wjnsdoniwt (maictggrsx ) View more	Positive	12 Aug 2024
NCT01906385 (ReSPECT-GBM, Corporate Publications) Manual	Phase 1/2	Recurrent Glioblastoma	15	186RNL	jeqlzklzrl(ezpnywkdzf) = ijofyrjefs umcqdxvxut (xveghifirs ) View more	Positive	20 Nov 2023
RESPECT-GBM (SNO2023)	Phase 1/2	Recurrent Glioma	27	Rhenium-186 Nanoliposome (186RNL) (186RNL dose <100 Gy)	tzccnncugy(kgemwuwduf) = weakness, fatigue, headache, seizure, scalp discomfort after CED wgyubnwfpd (uavzzarzes )	Positive	10 Nov 2023
RESPECT-GBM (SNO2023)	Phase 1/2	Recurrent Glioma	27	Rhenium-186 Nanoliposome (186RNL) (186RNL dose ≥100 Gy)		Positive	10 Nov 2023
NCT01906385 (SNMMI2023)	Phase 1/2	Recurrent Glioma	-	186RNL (Rhenium-186 Nanoliposome)	faokrdkwmz(xupuyrpipx) = Most AEs were mild or moderate (Grade 1 or 2) and non-serious. In general, AEs were deemed by the principal investigator to be unrelated to treatment, with exception to 1 case of scalp discomfort considered related to the surgical procedure and 1 case of cerebral edema considered possibly related to ¹⁸⁶RNL and/or tapering of oral corticosteroids bykohdrcfn (lahlsmpyek )	-	28 Aug 2023
NCT05034497 (SNMMI2023)	Phase 1	Metastatic Malignant Neoplasm to the Leptomeninges	-	186RNL (Rhenium-186 Nanoliposome)	igmgvcyqoo(jjdjlbpmkg) = the most common AE was headache osejqshwux (fhqbwyzgmr )	-	28 Aug 2023
NCT05034497 (ReSPECT-LM, NEWS) Manual	Phase 1/2	Meningeal Neoplasms	10	186RNL	khmiqolrsc(kzqaroddmq) = xgxnfifuun tnokgnfaao (ssfcchtdhp ) View more	Positive	11 Aug 2023
NCT01906385 (Corporate Publications) Manual	Phase 1/2	High grade glioma \| Familial Ependymoma	23	190RNL (Gy＜100)	nzkweppswj(empdgzdyas) = The AE’s with the highest incidence included fatigue (50%), muscular weakness (33.3%), headache (33.3%), and gait disturbance (27.8%) ijxmjurqrc (kabcrhltyb )	Positive	21 Nov 2022
NCT01906385 (Corporate Publications) Manual	Phase 1/2	High grade glioma \| Familial Ependymoma	23	190RNL (Gy＞100)		Positive	21 Nov 2022
NCT05034497 (ReSPECT-LM, Corporate Publications) Manual	Phase 1	Meningeal Leukemia	4	186RNL	ufelyhsddf(mcjijibglx) = ssriumpfwo wilmvgaxmk (wunzxoihzo )	Positive	19 Oct 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Retreatment Rhenium Liposome

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation